Erica D Warlick

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. doi request reprint Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type
    Erica D Warlick
    Blood and Marrow Transplant Program, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 21:357-63. 2015
  2. pmc Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Onco Targets Ther 3:157-65. 2010
  3. pmc Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 20:202-8. 2014
  4. pmc Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation
    Erica D Warlick
    Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:480-6. 2012
  5. pmc Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
    Erica Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 119:4083-90. 2012
  6. doi request reprint Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
  7. doi request reprint Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Leuk Lymphoma 52:2045-9. 2011
  8. pmc Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas
    Erica D Warlick
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 17:1025-32. 2011
  9. doi request reprint Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions
    Erica D Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Oncol 22:150-4. 2010
  10. doi request reprint Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Res 35:757-61. 2011

Detail Information

Publications14

  1. doi request reprint Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type
    Erica D Warlick
    Blood and Marrow Transplant Program, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 21:357-63. 2015
    ..Transplantation-related mortality was similar across donor types. In summary, our data support the use of alternative donors as a graft source with MA or RIC for patients with acute myeloid leukemia when a sibling donor is unavailable...
  2. pmc Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Onco Targets Ther 3:157-65. 2010
    ..This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS...
  3. pmc Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 20:202-8. 2014
    ..If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required. ..
  4. pmc Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation
    Erica D Warlick
    Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:480-6. 2012
    ..The lower DLI dose regimen improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD...
  5. pmc Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
    Erica Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 119:4083-90. 2012
    ..Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1...
  6. doi request reprint Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
    ....
  7. doi request reprint Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Leuk Lymphoma 52:2045-9. 2011
    ..We review the current literature regarding natural killer (NK) cell, T cell, and myeloid derived suppressor cell abnormalities in the spectrum of MDS...
  8. pmc Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas
    Erica D Warlick
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 17:1025-32. 2011
    ....
  9. doi request reprint Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions
    Erica D Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Oncol 22:150-4. 2010
    ..This review highlights strategies to optimize transplant for MDS and identifies unresolved questions...
  10. doi request reprint Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Res 35:757-61. 2011
    ..Our data suggest that exposure to consolidation chemotherapy prior to RIC HCT may not improve post-transplant outcomes for patients with AML in CR1...
  11. doi request reprint Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome
    Celalettin Ustun
    Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 21:866-72. 2015
    ..MK cytogenetics in MDS are associated with poor survival, suggesting the need for alternative or intensified approaches to their treatment. ..
  12. pmc Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
    Veronika Bachanova
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    Clin Cancer Res 21:1267-72. 2015
    ..We conducted a phase I dose-escalation study to assess the safety, maximum tolerated dose, and preliminary efficacy of DT2219 in patients with relapsed/refractory B-cell lymphoma or leukemia...
  13. pmc Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients
    Daniel F Pease
    Department of Medicine, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415, United States Electronic address
    Cancer Epidemiol 39:222-8. 2015
    ..This study determines whether therapeutic choices for newly diagnosed MDS are associated with location of treatment (community or academic), prognostic risk category, and patient age...
  14. pmc Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival
    Brian L McClune
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
    Biol Blood Marrow Transplant 20:960-8. 2014
    ..Even for patients age ≥55 years, OS still approached 40% at 3 years, suggesting that HCT affects long-term remission and remains underused in qualified older patients with NHL...